Improving the Fmoc solid phase synthesis of the cyclic hexapeptide complement C5a antagonist, PMX205

International Journal of Peptide Research and Therapeutics

Volumn 17, Issue 4, 2011, Pages 337-342

  Delisle Milton, R C ^a   Milton, S C ^a   Chamberlin, A R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

C5a antagonist; Cyclic peptide; Fmoc solid phase synthesis; Optimization; PMX205

Indexed keywords

CHEMICAL COMPOUND; COMPLEMENT COMPONENT C5 INHIBITOR; CYCLO(ARGINYLTRYPTOPANYL DEXTRO CYCLOHEXYLALANYLPROLYLORNITHINE)HYDROCINNAMATE; PENTAFLUOROPHENYLDIPHENYLPHOSPHINATE; PMX 205; UNCLASSIFIED DRUG;

ARTICLE; CHEMICAL INTERACTION; CHEMICAL REACTION KINETICS; CONTROLLED STUDY; CYCLIZATION; DRUG STRUCTURE; DRUG SYNTHESIS; PEPTIDE ANALYSIS; PEPTIDE SYNTHESIS; SOLID PHASE SYNTHESIS; STRUCTURE ANALYSIS; SUBSTITUTION REACTION;

RODENTIA;

EID: 81355160960     PISSN: 15733149     EISSN: 15733904     Source Type: Journal    
DOI: 10.1007/s10989-011-9273-9     Document Type: Article

References (19)

1. Abbenante G, Fairlie DP, Reid RC (2007) Process for the preparation of cyclic peptides. US patent 2007/0245926 A1
2. RR Ager ML Fonseca S-H Chu, et al. 2010 Microglial C5aR (CD88) expression correlates with amyloid-β deposition in murine models of Alzheimer's disease J Neurochem 113 389 401 20132482 10.1111/j.1471-4159.2010.06595.x 1:CAS:528:DC%2BC3cXksVChtbo%3D
3. F Albericio N Kneib-Cordonier S Biancalana, et al. 1990 5-(4-(9-fluorenylmethyloxycarbonyl)aminomethyl-3,5-dimethoxyphenoxy)-valeric acid (PAL) handle for the solid-phase synthesis of C-terminalpeptide amides under mild conditions J Org Chem 55 3730 3743 10.1021/jo00299a011 1:CAS:528:DyaK3cXktVKku7s%3D (Pubitemid 20296596)
4. KA Carpenter G Weltrowska BC Wilkes R Schmidt PW Schiller 1994 Spontaneous diketopiperazine formation via end-to-end cyclization of a nonactivated linear tripeptide: an unusual chemical reaction J Am Chem Soc 116 8450 8458 10.1021/ja00098a003 1:CAS:528:DyaK2MXktlCjtA%3D%3D (Pubitemid 24315626)
5. LA Carpino 1993 1-Hydroxy-7-azabenzotriazole. An efficient peptide coupling additive J Am Chem Soc 115 4397 4398 10.1021/ja00063a082 1:CAS:528:DyaK3sXkslejurc%3D
6. Chan WC, White PD (2004) Basic procedures. In: Chan WC, White PD (eds) Fmoc solid phase peptide synthesis-a practical approach. Oxford University Press, Oxford, pp 41-76
7. S Chen J Xu 1991 Pentafluorophenyl diphenylphosphinate a new efficient coupling reagent in peptide chemistry Tetrahedron Lett 32 6711 6714 10.1016/S0040-4039(00)93583-4 1:CAS:528:DyaK38XlvF2ksg%3D%3D
8. A El-Faham F Albericio 2010 COMU: a third generation of uranium-type coupling reagents Pept Sci 16 6 9 10.1002/psc.1204 1:CAS:528:DC%2BD1MXhsFentr3O
9. KA Fairweather N Sayyadi IJ Luck JK Clegg KA Joliffe 2010 Synthesis of all L-cyclic tetrapeptides using pseudoprolines as removable turn indicators Org Lett 12 3136 3139 20565133 10.1021/ol101018w 1:CAS:528:DC%2BC3cXnvVKqsLY%3D
10. Fields GB (1995) Methods for removing the Fmoc group. In: Pennington MW, Dunn BM (eds) Methods in molecular biology, vol 35. Springer Protocols, Humana Press, New York, pp 17-27
11. ML Fonseca RR Ager S-H Chu, et al. 2009 Treatment with a C5aR antagonist decreases pathology and enhances behavioral performance in murine models of Alzheimer's disease J Immunol 183 1375 1383 19561098 10.4049/jimmunol.0901005 1:CAS:528:DC%2BD1MXotFWgsbg%3D
12. E Kaiser RL Colescott CD Bossinger PI Cook 1970 Color test for detection of free terminal amino groups in the solid-phase synthesis of peptides Anal Biochem 34 595 598 5443684 10.1016/0003-2697(70)90146-6 1:CAS:528: DyaE3cXhtVWjur0%3D
13. E Kaiser CD Bossinger RL Colescott DB Olsen 1980 Color test for terminal prolyl residues in the solid-phase synthesis of peptides Anal Chim Acta 118 149 151 10.1016/S0003-2670(01)93726-2 1:CAS:528:DyaL3MXkslOhug%3D%3D
14. J Köhl 2006 Drug evaluation: the C5a receptor antagonist PMX53 Curr Opin Mol Ther 8 529 538 17243489 (Pubitemid 44921809)
15. Lawhon C (2009) Drug rescues memory lost to Alzheimer's disease. U.C. Irvine Communications: UCIrvine Today, July 14, 2009
16. Mellor SL, Wellings DA, Fehrentz J-A et al (2004) Synthesis of modified peptides. In: Chan WC, White PD (eds) Fmoc solid phase peptide synthesis-a practical approach. Oxford University Press, Oxford, pp 137-181
17. E Pedroso A Grandas X de las Heras R Eritja E Giralt 1986 Diketopiperazine formation in solid phase peptide synthesis using p-alkoxybenzyl ester resins and Fmoc amino acids Tetrahedron Lett 27 743 746 10.1016/S0040-4039(00)84089-7 1:CAS:528:DyaL2sXltVKisQ%3D%3D
18. R Reid G Abbenante SM Taylor DP Fairlie 2003 A convergent solution phase synthesis of the macrcocycle Ac-Phe-[Orn-Pro-D-Cha-Trp-Arg], a potent new antiinflammatory drug J Org Chem 68 4464 4471 12762752 10.1021/jo034228r 1:CAS:528:DC%2BD3sXjsVOjt7c%3D (Pubitemid 36622736)
19. TM Woodruff KJ Constantini JW Crane, et al. 2008 The complement factor C5a contributes to pathology in a rat model of amyotrophic lateral sclerosis J Immunol 181 8727 8734 19050293 1:CAS:528:DC%2BD1cXhsVCktrrM